Champions Biotechnology Inc. focuses on oncology drug developments and preclinical platforms and data to enhance and accelerate the value of those drugs. The company today announced an exclusive licensing agreement with Yale University and Southern Research Institute for the development of Bithionol for cancer treatment.

According to scientists from Yale and Southern Research, Bithionol, which is available for parasitic infections, shows activity against solid cancerous tumors and may be effective in treating melanoma, prostate, breast, lung and other cancers.

Per the agreement, Yale and Southern Research will receive an upfront payment, as well as milestone payments and royalties; Champions has exclusive rights for continued development of Bithionol for all oncology applications, and will use its predictive Biomerk Tumorgraft platform to determine optimal applications and efficient clinical development. If Champions is able to deliver results, the company will conduct human clinical trials.

“We are excited to work with Champions’ experienced scientific

...

TapImmune Inc. is a biotechnology company headquartered in Bellevue, Washington. They specialize in the development of immunotherapeutic vaccines for cancer and infectious diseases. Their core business focus is on emerging technologies based on cellular immunology and genetic understanding of the cause and potential novel treatments of disease.

TapImmune Inc.’s lead product is the TAP vaccine. It performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers. Therefore, the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. In addition, the TAP molecule works as an adjuvant (accelerant) to enhance targeted vaccines against infectious diseases.

The Company is developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The expectation is that the global vaccine market will grow from $13 billion in 2007 to $21 billion

...

Rosetta Genomics (NASDAQ:ROSG) today announced an update regarding their colon cancer diagnostic program and said that Ayelet Chajut, Executive Vice President, R&D, Head of Molecular Biology will speak more about this program at the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS-VI). The conference will held from November 9 to November 11 in Hong Kong where they will present a new generation of molecular diagnostic markers that will help in the treatment and diagnosis of colon cancer. Rosetta Genomics is one of the leading molecular diagnostics companies that develops and commercializes molecular diagnostic products based on its proprietary microRNAs. The company is also developing and discovering early detection cancer screening products, including a colon cancer screening test. Rosetta Genomics have their labs in Philadelphia where they perform commercial molecular diagnostics tests in order to discover and develop new diagnostics markers.

During the update, Rosetta Genomics pointed

...

GlaxoSmithKline (GSK) recently received a positive recommendation from the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) for its cervical cancer vaccine, Cervarix. The CDC has recommended that Cervarix should be given to girls and young women to protect against cervical pre-cancers and cervical cancer caused by oncogenic human papillomavirus (HPV) 16 and 18.   The committee also recommended that the vaccine should be used in 11 and 12 year old girls specifically and in girls and young women who have not yet been vaccinated. Cervarix, which received approval in the U.S. recently, is indicated for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic HPV types 16 and 18 for use in girls and young women (aged 10-25).   The ACIP’s recommendation should help increase adoption of the vaccine, which is slated to hit the U.S. market later this ...

BEVERLY, Mass., Oct. 19, 2009 (GLOBE NEWSWIRE) — Cellceutix Corporation (OTCBB:CTIX) today announced that data recently presented by the Company at the American Association for Cancer Research (AACR) along with other data developed by the Company indicate that Kevetrin is selectively targeting very specific anti-tumor pathways, such as AKT and p38 MAP kinase. The data presented at the AACR showed that Kevetrin was less cytotoxic than paclitaxel, cisplatin and 5FU while having better anti-tumor activity in two multi-drug resistant lung cancer cell lines. This indicates that Kevetrin is not acting primarily as a cytotoxic agent but may be targeting specific components of the signal transduction pathway, such as AKT and p38 MAP kinase. The Company is continuing to explore other potential targets.

Other data developed by the Company indicate that Kevetrin has potent anti-tumor activity in one cell line (MDA-MB–231) despite only partially inhibiting AKT in that cell line.

...

GlaxoSmithKline (GSK) received good news last week with the receipt of approval from the US Food and Drug Administration (FDA) for its cervical cancer vaccine, Cervarix. The vaccine received approval for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25). Last month, an advisory committee of the FDA had voted 12-1 in favor of the efficacy of the vaccine and 11-1 in support of its safety. Cervarix also received approval in Japan for girls aged 10 and above, becoming the first cervical vaccine to gain approval in Japan. The American Cancer Society estimates that about 11,000 women will be diagnosed with cervical cancer and 4,000 women will die from the disease in 2009 in the US. Globally, more than 500,000 women are expected to be diagnosed with cervical ...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings, Inc. (OTCBB: CSRH) has launched its mobile check cashing program. The introduction of this service will offer those that are currently using check cashing facilities a much more convenient way to cash their payroll checks. After two years of development with its partners, Consorteum has now proceeded to the pilot phase of its check cashing program in the Toronto, Ontario region. The first stage of the pilot implementation will be the deployment of this new service on

...

Obesity is a leading risk factor behind many cardiovascular diseases, cancers and type 2 diabetes. According to the Centers for Disease Control and Prevention, in the past 20 years there has been a dramatic increase in obesity. Though public awareness has prompted more Americans to hit the gym and lead healthier lifestyles, calories and fat in beverages such as juices, energy and soft drinks are often overlooked, subtly contributing to weight-gain and health issues.

Celsius Holdings Inc. has developed an original drink to generate the opposite effect. The company’s Celsius® calorie burning beverage has been scientifically proven to burn approximately 100 calories per can through boosting metabolism and providing sustained energy over a three-hour period.

The company today announced increased availability of Celsius, as the product is available at approximately 1,800 SUPRERVALU stores.

“We are thrilled to be carried by SUPERVALU, a leading grocery retailer with unsurpassed recognition in the

...

In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

...

Stocks are lower as a weaker U.S. dollar help lift commodity prices and Johnson & Johnson’s third-quarter sales figures disappointed investors

Stocks fell on Tuesday after disappointing quarterly sales figures from economic bellwether Johnson & Johnson (NYSE: JNJ) sparked worries about consumer spending, offsetting a lift from higher commodity prices.

The Nasdaq gave up its initial gains at the open.

The Dow Jones industrial average was down 53.66 points, or 0.54 percent, at 9,832.14. The Standard & Poor’s 500 Index was down 7.19 points, or 0.67 percent, at 1,069.00. The Nasdaq Composite Index was down 5.16 points, or 0.24 percent, at 2,133.98.

Yesterday’s Top Performing Small Cap Stock:

GWS Technologies, Inc, (OTC BB: GWSC) was a SmallCapVoice.com top performer yesterday closing up over 8% on trading volume of 19,747 shares.

GWS stands for GreenWindSolar. GWSC is a renewable energy technology company developing and marketing solar and wind-powered renewable energy products and solutions. Our

...